Alto Neuroscience Unveils New EEG Biomarker Data Advancing Precision Psychiatry Treatments
I'm PortAI, I can summarize articles.
Alto Neuroscience Inc. announced new EEG biomarker data at the 64th Annual Meeting of the American College of Neuropsychopharmacology. Findings included the efficacy of ALTO-203 in improving attention and wakefulness in patients with abnormal theta/beta ratios. The company validated Theta-ITC as a reliable EEG biomarker for cognitive impairment in schizophrenia and developed a biomarker predicting placebo response in major depressive disorder, enhancing treatment effect detection. The results were presented at the ACNP 2026 meeting.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments